Don't Miss


Just Published: Malignant Melanoma: PD-1 inhibitors revolutionise treatment is a comprehensive report with insights from 12 leading US and European KOLs offering their latest views on current and late-stage pipeline products, why and when they would prescribe them, and the factors likely to affect their future positioning and competitiveness.Learn more.

Bristol-Myers Squibb reports promising survival data for PD-1 inhibitor Opdivo in mid-stage lung cancer trial